Table 2

Base-case scenario results from the discrete-event simulation model

	UK			Spain
	Eplerenone	Standard care	Difference	Eplerenone	Standard care	Difference
Other CV hospitalisations	1.27	1.23	0.04	As UK
HF hospitalisations	1.32	1.60	−0.28
Diagnosis of atrial fibrillation	0.09	0.12	−0.03
CV mortality	0.71	0.77	−0.05
Non-CV mortality	0.08	0.06	0.02
Adverse events	0.67	0.43	0.24
ICD or CRT	0.59	0.46	0.13
Discontinuation of eplerenone	0.42	–	0.42
Cost of CV hospitalisations	£3236	£3240	−£4	€5493	€5478	€15
Cost of HF hospitalisations	£3888	£4862	−£973	€3815	€4748	−€932
Cost of active treatment	£3873	£0	£3873	€7080	€0	€7080
Cost of concomitant treatment	£1773*	£1426	£347	€2371	€1889	€481
Cost of devices	£3597*	£3046	£551	€3641	€3048	€592
Cost of disease management and monitoring	£3433*	£2761	£672	€488	€389	€99
Cost of adverse events	£137	£108	£30	€465	€443	€22
Total cost	£18 559	£14 275	£4284	€23 353	€15 995	€7358
Total QALYs	6.19	4.98	1.22	6.53	5.20	1.33
Total life years	7.74	6.23	1.52	8.18	6.52	1.66
ICER	£3520			€5532
Cost per life year gained	£2825			€4431

*While the rate of use of devices, management and monitoring, and concomitant treatment requirements is either the same for the two arms or lower on the eplerenone arm, as patients are expected to live longer, the total cost over a patient's lifetime is higher.
CRT, cardiac resynchronisation therapy; CV, cardiovascular; HF, heart failure; ICD, implantable cardioverter-defibrillator; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.